



ABSTRACT CATEGORIES

The AACR Annual Meeting 2024 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the AACR Annual Meeting 2024. Please note that these abstract categories may or may not be used as AACR Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is **November 16, 2023 (11:59 p.m. ET)** and the late-breaking and clinical trials abstract submission deadline is **January 8, 2024 (11:59 p.m. ET)**.

The abstract categories are listed in alphabetical order.

BCS Bioinformatics, Computational Biology, Systems Biology, and Convergent Science

BCS01 Bioinformatics, Computational Biology, and Systems Biology (See also MCB08: Genomics)

- Analytic pipeline optimization
- Application of bioinformatics to cancer biology
- Artificial intelligence and machine/deep learning
- Database resources
- Integrative computational approaches
- Molecular modeling
- New algorithms
- New software tools for data analysis
- Sequence analysis
- Statistical methods
- Systems engineering
- Whole cell modeling
- Other

BCS02 Convergent Science

- Artificial intelligence and machine/deep learning
- Digital pathology
- Early detection and imaging
- Integration of clinical and research data
- Integrative cancer science
- Liquid biopsy: Multi-analyte and multi-omic
- Mathematical modeling
- Network biology and precision medicine
- Physical sciences in oncology
- Other

CH Chemistry

CH01 Drug Discovery, Design, and Delivery

- Basic and applied nanotechnology and therapeutics
- Chemoinformatics, in silico screening, and computational methods
- Drug delivery
- Drug design
- High-throughput screening (assays and libraries)
- Lead identification and optimization
- Natural products
- Synthesis, metabolism, and disposition
- Targeted protein degradation
- Other

CH02 Proteomics and Mass Spectrometry

- Biological mass spectrometry and systems biology
- Proteomics and biomarker discovery
- Proteomics and signaling networks
- Other

CH03 Structural and Chemical Biology

- Chemical genetics and genomics
- Small molecule, protein, and nucleic acid interactions
- Target identification, small molecule probes, and libraries
- X-ray and NMR structures
- Other

ABSTRACT CATEGORIES *(cont'd)*

Regular Abstract Submission Deadline:
November 16, 2023 (11:59 p.m. ET)
Late-Breaking and Clinical Trials Abstract
Submission Deadline: **January 8, 2024 (11:59 p.m. ET)**

CL Clinical Research

(not including clinical trials, see also the Clinical Trials [CT] categories)

CL01 Biomarkers

Biomarkers predictive of therapeutic benefit
Diagnostic biomarkers
Early detection biomarkers
Liquid biopsies: Circulating nucleic acids
Liquid biopsies: Circulating tumor cells
Metastasis biomarkers
Prognostic biomarkers
Spatial proteomics and transcriptomics
Other

CL02 Biostatistics in Clinical Trials

Design and analysis of clinical trials
New study designs: Theory, methodology, and modeling
Statistical modeling for cancer studies
Other

CL03 Clinical Endocrinology

(See also EN01: Molecular, Preclinical, and Clinical Endocrinology)

Endocrine-related cancers
Growth factors, receptors, and signal transduction
Hormone receptors and diagnosis/prognosis
Hormone signaling and inhibitors
Hormone synthesis, metabolism, and inhibitors
Neuroendocrine and other endocrine factors
Nuclear receptors: Structure and function
Preclinical studies of endocrine-related cancers
Receptors and signal transduction
Steroid hormone receptors
Other

CL04 Clinical Research in the Elderly

Aging, immunity, and cancer
Other

CL05 Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations

Biobanking/biospecimen collection
Clinical trial design
Community-engaged research/community-based participatory research
Community outreach and patient accrual
Other

CL06 Immuno-oncology

(See also ET01: Biological Therapeutic Agents; IM01: Preclinical Immunotherapy)

Adoptive cell therapy
Combination immunotherapies
Immune checkpoints
Immune mechanisms invoked by other therapies including chemotherapy
Immune mechanisms invoked by radiation therapy
Immune monitoring/clinical correlates
Immune response to therapies
Immunomodulatory agents and interventions
Inflammation, immunity, and cancer
Modifiers of the tumor microenvironment
Therapeutic antibodies, including engineered antibodies
Vaccines (oncolytic and prophylactic)
Other

CL07 Pediatric Cancer – Clinical Investigations

(See also CT07: Phase I, II, or III Clinical Trials in Pediatric Cancer; TB06: Pediatric Cancer - Basic Science)

Adolescent and young adult oncology
Childhood cancer drug development
Immunotherapeutic approaches to pediatric cancer
Pediatric cancer predisposition and surveillance
Survivorship, late effects, and second cancers
Therapeutic dosing, resistance, and combination therapy application
Translational pediatric cancer research
Other

CL08 Precision Oncology

Combination therapy
Molecular targeted therapy
Other

CL09 Radiation Oncology

(See TB07: Radiation Science; ET08: Preclinical Radiotherapeutics)
Clinical radiotherapeutic studies
Interventional radiology
Modification of radiosensitivity
Radiation therapy combinations
Radiation-induced late effects/second cancers
Radiation-induced resistance
Other

CL10 Real-World Data and Real-World Evidence

Analyses using clinico-genomic databases
Clinical informatics and data science
Retrospective clinical analyses
Other

CL11 Surgical Oncology (including Prophylactic Surgery)

Surgical intervention in early stage disease
Surgical intervention in late stage disease
Surgical outcomes after neoadjuvant therapy
Surgical palliation for local control
Surgical prophylaxis for high risk populations

CL12 Survivorship Research and Supportive Care

Biology of cell and tissue damage
Cardio-oncology
Comparative effectiveness research and cost-effective studies
Late effects of cancer and its treatment, including second cancers
Psycho-oncology
Supportive care, palliation, and pain management
Translational survivorship research
Other

CL13 Translational Research – Molecular Biology in Clinical Oncology

(See also TB03: In Vivo Imaging and Anatomical and Molecular Pathology)
Clinical imaging
Cytogenetics and clinical molecular genetics
Epigenetic therapy
Functional and molecular imaging
Molecular classification of tumors
Radiomics
Theranostics
Tumor staging: Correlation of clinical and molecular markers
Other

CT Clinical Trials

CT01 Clinical Trials in Progress

Phase I clinical trials in progress
Phase II clinical trials in progress
Phase III clinical trials in progress

CT02 Phase 0 Clinical Trials

Phase 0 clinical trials

CT03 First-in-Human Phase I Clinical Trials

First-in-human phase I clinical trials

CT04 Phase I Adult Clinical Trials

(See also ET07: Pharmacology, Pharmacogenetics, and Pharmacogenomics)
Phase I adult clinical trials

CT05 Phase II Adult Clinical Trials

Phase II adult clinical trials

CT06 Phase III Adult Clinical Trials

Phase III adult clinical trials

CT07 Phase I, II, or III Clinical Trials in Pediatric Cancer

(See also CL07: Pediatric Cancer Clinical Investigations; TB06: Pediatric Cancer Basic Science)
Phase I clinical trials in pediatric cancer
Phase II clinical trials in pediatric cancer
Phase III clinical trials in pediatric cancer

ABSTRACT CATEGORIES *(cont'd)*

Regular Abstract Submission Deadline:
November 16, 2023 (11:59 p.m. ET)
Late-Breaking and Clinical Trials Abstract
Submission Deadline: **January 8, 2024 (11:59 p.m. ET)**

MCB03 Cell Growth Signaling Pathways

Cell signaling
Cell-cell interactions
Growth factors
GTPases, their regulators, and effectors
Kinases and phosphatases
Receptors
Tumor-stromal cell interactions
Ubiquitin and ubiquitin-like proteins
Other

MCB04 Cellular Stress Responses

Hypoxia
Oxidative stress
Premature cellular aging
Senescence
Unfolded protein response
Other

MCB05 DNA Damage and Repair

Chromosomal structural alterations/
translocations
Genomic instability
Homologous recombination
Mechanisms of genomic alterations
Radiation-induced DNA damage
Other

MCB06 Epigenetics and Epigenomics

Chromatin structure and function
DNA methylation
Epigenetic changes as molecular
markers of cancer
Epigenomics
Gene silencing
Histone modification
Other

MCB07 Gene Regulation and Transcription Factors

Chromatin structure and function
Gene expression
Mechanisms of transcription
Oncogenic transcription factors
Posttranscriptional and translational
control
Promoters and enhancers of
transcription
Protein-protein interactions in
transcription factor function
Regulation of transcription factor
function
Transcriptional control of cell
differentiation
Other

MCB08 Genomics (See also BCS01: Bioinformatics, Computational Biology, and Systems Biology)

Functional genomics
Genomic profiling of tumors
High-throughput sequencing
Large-scale approaches to cancer gene
discovery
Microarrays
Other

MCB09 Metabolism and Cancer

Metabolic pathways
Metabolomics
Mitochondrial function
Signaling pathways that regulate
metabolism
Other

MCB10 microRNAs and Other Noncoding RNAs

Epigenetic control of miRNA expression
miRNA profiling in cancer
miRNA regulation of cancer biology
miRNA-based diagnostics
miRNA-based therapeutics
miRNAs as tumor suppressors/
oncogenes
Noncoding RNAs
Other

MCB11 Oncogenes and Tumor Suppressor Genes

Cytoplasmic signal transducers
Genotype/phenotype correlations
Nuclear oncoproteins and tumor
suppressor genes
Oncogene growth factors and their
receptors
Tumor suppressor genes
Other

PS Population Sciences (Including Diversity, Equity, and Inclusion)

PS01 Population Sciences

Aging as a risk factor
Biomarkers of endogenous or
exogenous exposures, early detection,
and biologic effects
Biomarkers of prognosis
Cancer disparities research
Descriptive epidemiology, covering
cancer incidence, mortality, clusters,
and trends
Diet, alcohol, tobacco use, and other
lifestyle risk factors
Environmental and occupational risk
factors
Familial and hereditary cancers
Functional studies of genetic variants
Gene-gene and gene-environment
interactions
Genome-wide association studies
(GWAS)/post-GWAS
Health services and comparative
effectiveness research
Implementation science
Infection and immune factors
Next-generation sequencing in
epidemiology studies (whole genome,
exome, targeted, or fine-mapping)
Pathway and candidate gene studies of
risk or prognosis
Pharmacoepidemiology
Preneoplastic and tumor markers
Primary and secondary intervention
studies
Psychosocial and behavioral
epidemiology
Risk prediction models for incidence,
prognosis, and/or mortality
Screening and early detection
Statistical and epidemiological
methodology
Survivorship research
Other

PR Prevention, Early Detection, and Interception (Including Diversity, Equity, and Inclusion)

PR01 Clinical Prevention, Early Detection, and Interception

Application of molecular pathology in
clinical prevention
Biomarkers and intervention studies
Cancer disparities research
Cancer surveillance and screening
studies
Chemoprevention clinical trials
Genomics and proteomics in cancer risk
and response assessment
Infections and virus-related cancers
Microbiome and prevention
Obesity, diet, physical activity, and
energy balance
Prevention and treatment of
pre-malignant lesions (intraepithelial
neoplasia)
Prevention of second cancers
Quality of life/late effects/survivorship
Recruitment of racial and ethnic
minorities and other underserved
populations in clinical prevention trials
Screening and early detection
Other

PR02 Preclinical Prevention, Early Detection, and Interception

Animal models in prevention
Behavioral sciences and prevention
Biological and biochemical mechanisms
in prevention
Biomarkers and intervention studies
Cancer communication and decision
making
Cellular models
Chemoprevention studies
Diet, nutrition, and cancer
Microbiome and prevention
Molecular markers in prevention
research
Molecular targets for prevention
New agent development
Screening and early detection
Other

ABSTRACT CATEGORIES *(cont'd)*

Regular Abstract Submission Deadline:
November 16, 2023 (11:59 p.m. ET)
Late-Breaking and Clinical Trials Abstract
Submission Deadline: **January 8, 2024 (11:59 p.m. ET)**

RSP Regulatory Science and Policy

RSP01 Regulatory Science and Policy

Biosimilars and generics
Clinical trial design and accrual
Combination therapies and codevelopment of investigational agents and diagnostics
Data science and informatics
International regulatory issues
Novel endpoints and biomarkers
Real-world evidence and retrospective analyses
Tobacco and e-cigarette regulation
Other

SHP Science and Health Policy

SHP01 Science and Health Policy

Cancer disparities
Cancer survivorship
Implementation science
Patient advocacy and engagement
Value and cost issues in cancer care
Other

TB Tumor Biology

TB01 Angiogenesis

Angiogenesis and angiogenesis inhibitors
Host-tumor interactions
Molecular mechanisms of angiogenesis
Novel pro- and antiangiogenic factors
Tumor microcirculation and the microenvironment
Other

TB02 Carcinogenesis

Chemical, environmental, and virus-induced carcinogenesis
Mutagenesis
Other

TB03 In Vivo Imaging and Anatomical and Molecular Pathology (See also CL13: Translational Research: Molecular Biology in Clinical Oncology)

Advanced nanotechnology and imaging
Application of imaging technology to the clinic
Imaging in animal models
Imaging of molecular and cellular events in the tumor microenvironment
Imaging of molecular and cellular events in tumors and tumor cells
Imaging the immune response
Imaging tumor metabolism
New targets for imaging
Other

TB04 Metastasis

Actin cytoskeleton
Biomarkers of metastasis
Epithelial/mesenchymal transition (EMT and MET)
Expression profiling of tumor progression and metastasis
Genes that regulate migration and invasion
Imaging of tumor progression and metastasis
Invasion and migration
Metastasis-promoting genes
Metastasis suppressor genes
Premetastatic niche
Therapeutic metastasis prevention
Other

TB05 Nonclinical Models of Cancer

3-D and tissue recombinant models
Developmental phenotypes of cancer genes
Human-in-mouse models of human cancer
Model organisms in drug discovery
Mouse models of human cancer
Noninvasive imaging in animal models
Organoids
Other animal and cell models of cancer
Patient-derived xenograft models
Zebrafish models of cancer
Other

TB06 Pediatric Cancer - Basic Science (See also CL07: Pediatric Cancer - Clinical Investigations; CT07: Phase I, II, or III Clinical Trials in Pediatric Cancer)

Developmental origins and drivers of pediatric cancer
Pediatric cancer genomics and epigenomics
Pediatric cancer models
Pediatric cancer tumor microenvironment and tumor heterogeneity
Other

TB07 Radiation Science

(See also CL09: Radiation Oncology; ET08: Preclinical Radiotherapeutics)
Modulators of radiation response
Photobiology/photodynamic therapy
Radiation dose fractionation
Radiation-activated signaling pathways
Radiation-induced gene expression
Radiation-induced resistance
Radiobiology research
Radioprotectors and radiosensitizers
Other

TB08 Stem Cell Biology

Adult stem cells
Cancer stem cells
Developmental pathways in cancer
Embryonic stem cells
Stem cell markers
Stem cells and regenerative medicine in oncology
Other

TB09 Tumor Adhesion

Cell adhesion and extracellular matrix
Drug resistance
Other

TB10 Tumor Evolution and Heterogeneity

Causes and consequences of tumor heterogeneity
Clonal evolution
Methods to measure tumor evolution and heterogeneity
Other

TB11 Tumor Microenvironment

Chemokines in the microenvironment
Drug targets in the microenvironment
Extracellular matrix and integrins
Gene expression in the microenvironment
Immune cells in the tumor microenvironment
Inflammatory cells as regulators of tumor growth
Microbiome
Organ-specific microenvironments
Proteases and inhibitors in the microenvironment
Tumor dormancy
Tumor/stromal interactions
Tumor-immune system interactions
Other